RE:RE:RE:RE:RE:of value to non TST bagholders and brought hereAh sry I was replying while you were mate.
To your point: it is not the case that all cancer drugs get priority approval, but mostcancer drugs start off 3L or 4L therapies, then work forward (see Roche's Pertuzumab trial readout and filing timeline as a nice case study)
However, this is not the case with TST, so for the reasons in my other replynfew minutes ago, I do think you are probably right on MCNA